Insight, China's Pharmaceutical Industry

Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers

Chongqing Maile Bio-Pharm Co. Ltd. and Shenzhen Main Luck Pharmaceuticals Inc. announced a strategic partnership...

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Fineline Cube Mar 24, 2026

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), China’s pharmaceutical distribution leader, announced a licensing agreement with...

Company

Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface

Fineline Cube Mar 24, 2026

Insilico Medicine (HKG: 3696) announced the launch of PandaClaw, a transformative new feature of its...

Company Deals

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Fineline Cube Mar 24, 2026

Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,...

Company Drug

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

Fineline Cube Mar 24, 2026

Qilu Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 innovative drug, QLS1317 tablets, has...

Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Fineline Cube Mar 24, 2026

China’s National Healthcare Security Administration (NHSA) held a briefing outlining the DRG (Diagnosis‑Related Groups) Grouping...

Company Deals

Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers

Fineline Cube Mar 24, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has entered into a strategic partnership...

Company Drug

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Fineline Cube Mar 24, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp...

Company Deals

Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India

Fineline Cube Mar 24, 2026

Bio‑Thera Solutions Inc. (SHA: 688177) has expanded its strategic partnership with Intas Pharmaceuticals Ltd., granting...

Company

Sanofi Upgrades Shanghai R&D Center to Legal Entity – Largest China Translational Medicine Hub Anchors Global Network

Fineline Cube Mar 24, 2026

Sanofi S.A. (NASDAQ: SNY) announced a comprehensive strategic upgrade of its China R&D center, establishing...

Company Drug

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

Fineline Cube Mar 24, 2026

RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced NMPA approval for a new indication of...

Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Fineline Cube Mar 23, 2026

Novartis AG (NYSE: NVS) announced at the China Development Forum (CDF) 2026 Annual Meeting that...

Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Fineline Cube Mar 23, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that HLX18, a recombinant humanized anti‑PD‑1 monoclonal antibody...

Company Deals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Fineline Cube Mar 23, 2026

Everest Medicines Limited (HKG: 1952) has entered into an asset acquisition agreement with Corxel Pharmaceuticals...

Company Drug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Fineline Cube Mar 23, 2026

Lepu Biopharma Co., Ltd. (HKG: 2157) announced NMPA IND approval for a groundbreaking Phase II/III...

Company

Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates

Fineline Cube Mar 23, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5%...

Company Drug

Biokin Pharma’s BL‑ARC002 Wins NMPA Approval – First‑in‑Class Antibody‑Radionuclide Conjugate Enters Solid Tumor Trials

Fineline Cube Mar 23, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL‑ARC002 injection, a Category 1...

Company Drug

Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs – HS‑20152 and HS‑10587 Enter Clinical Trials in Rare Disease and Oncology

Fineline Cube Mar 23, 2026

Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have...

Company Deals Drug

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Fineline Cube Mar 23, 2026

Novartis AG (NYSE: NVS) announced a definitive agreement to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor,...

Company Drug

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

Fineline Cube Mar 23, 2026

Grand Pharmaceutical Group (HKG: 0512) announced that its licensed‑in global innovative ophthalmic drug GPN01768 [TP‑03,...

Insight, China's Pharmaceutical Industry

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma

Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India

Sanofi Upgrades Shanghai R&D Center to Legal Entity – Largest China Translational Medicine Hub Anchors Global Network

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates

Biokin Pharma’s BL‑ARC002 Wins NMPA Approval – First‑in‑Class Antibody‑Radionuclide Conjugate Enters Solid Tumor Trials

Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs – HS‑20152 and HS‑10587 Enter Clinical Trials in Rare Disease and Oncology

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

You Missed

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma

Kelun‑Biotech Reports 2025 Revenue RMB 2.06 Billion – Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification

Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China